OBJECTIVES: The objective of this project was to assess a pediatric institution's use of infliximab and develop and evaluate electronic health record tools to improve safety and efficiency of infliximab ordering through auditing and improved communication. METHODS: Best use of infliximab was defined through a literature review, analysis of baseline use of infliximab at our institution, and distribution and analysis of a national survey. Auditing and order communication were optimized through implementation of mandatory indications in the infliximab orderable and creation of an interactive flowsheet that collects discrete and free-text data. The value of the implemented electronic health record tools was assessed at the conclusion of the project. RESULTS: Baseline analysis determined that 93.8% of orders were dosed appropriately according to the findings of a literature review. After implementation of the flowsheet and indications, the time to perform an audit of use was reduced from 60 minutes to 5 minutes per month. Four months post implementation, data were entered by 60% of the pediatric gastroenterologists at our institution on 15.3% of all encounters for infliximab. Users were surveyed on the value of the tools, with 100% planning to continue using the workflow, and 82% stating the tools frequently improve the efficiency and safety of infliximab prescribing. CONCLUSIONS: Creation of a standard workflow by using an interactive flowsheet has improved auditing ability and facilitated the communication of important order information surrounding infliximab. Providers and pharmacists feel these tools improve the safety and efficiency of infliximab ordering, and auditing data reveal that the tools are being used.
OBJECTIVES: The objective of this project was to assess a pediatric institution's use of infliximab and develop and evaluate electronic health record tools to improve safety and efficiency of infliximab ordering through auditing and improved communication. METHODS: Best use of infliximab was defined through a literature review, analysis of baseline use of infliximab at our institution, and distribution and analysis of a national survey. Auditing and order communication were optimized through implementation of mandatory indications in the infliximab orderable and creation of an interactive flowsheet that collects discrete and free-text data. The value of the implemented electronic health record tools was assessed at the conclusion of the project. RESULTS: Baseline analysis determined that 93.8% of orders were dosed appropriately according to the findings of a literature review. After implementation of the flowsheet and indications, the time to perform an audit of use was reduced from 60 minutes to 5 minutes per month. Four months post implementation, data were entered by 60% of the pediatric gastroenterologists at our institution on 15.3% of all encounters for infliximab. Users were surveyed on the value of the tools, with 100% planning to continue using the workflow, and 82% stating the tools frequently improve the efficiency and safety of infliximab prescribing. CONCLUSIONS: Creation of a standard workflow by using an interactive flowsheet has improved auditing ability and facilitated the communication of important order information surrounding infliximab. Providers and pharmacists feel these tools improve the safety and efficiency of infliximab ordering, and auditing data reveal that the tools are being used.
Keywords:
EHR tool; EMR tool; Epic; drug audit; infliximab
Authors: Michael Clark; Jean-Frederic Colombel; Brian C Feagan; Richard N Fedorak; Stephen B Hanauer; Michael A Kamm; Lloyd Mayer; Carol Regueiro; Paul Rutgeerts; William J Sandborn; Bruce E Sands; Stefan Schreiber; Stephan Targan; Simon Travis; Severine Vermeire Journal: Gastroenterology Date: 2007-07 Impact factor: 22.682
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Bhupinder K Sandhu; John M E Fell; R Mark Beattie; Sally G Mitton; David C Wilson; Huw Jenkins Journal: J Pediatr Gastroenterol Nutr Date: 2010-02 Impact factor: 2.839
Authors: Jean Frédéric Colombel; William J Sandborn; Walter Reinisch; Gerassimos J Mantzaris; Asher Kornbluth; Daniel Rachmilewitz; Simon Lichtiger; Geert D'Haens; Robert H Diamond; Delma L Broussard; Kezhen L Tang; C Janneke van der Woude; Paul Rutgeerts Journal: N Engl J Med Date: 2010-04-15 Impact factor: 91.245
Authors: Roy Nattiv; Janet M Wojcicki; Elizabeth A Garnett; Neera Gupta; Melvin B Heyman Journal: World J Gastroenterol Date: 2012-03-21 Impact factor: 5.742
Authors: Nicolino Ruperto; Daniel J Lovell; Ruben Cuttica; Nick Wilkinson; Patricia Woo; Graciela Espada; Carine Wouters; Earl D Silverman; Zsolt Balogh; Michael Henrickson; Maria-Teresa Apaz; Eileen Baildam; Anders Fasth; Valeria Gerloni; Pekka Lahdenne; Anne-Marie Prieur; Angelo Ravelli; Rotraud K Saurenmann; Maria Luz Gamir; Nico Wulffraat; Laszlo Marodi; Ross E Petty; Rik Joos; Francesco Zulian; Deborah McCurdy; Barry L Myones; Kalman Nagy; Peter Reuman; Ilona Szer; Suzanne Travers; Anna Beutler; Greg Keenan; Jason Clark; Sudha Visvanathan; Adedigbo Fasanmade; Aparna Raychaudhuri; Alan Mendelsohn; Alberto Martini; Edward H Giannini Journal: Arthritis Rheum Date: 2007-09
Authors: Robert Baldassano; Christian P Braegger; Johanna C Escher; Kimberly DeWoody; David F Hendricks; Gregory F Keenan; Harland S Winter Journal: Am J Gastroenterol Date: 2003-04 Impact factor: 10.864
Authors: Dan Turner; Arie Levine; Johanna C Escher; Anne M Griffiths; Richard K Russell; Axel Dignass; Jorge Amil Dias; Jiri Bronsky; Christian P Braegger; Salvatore Cucchiara; Lissy de Ridder; Ulrika L Fagerberg; Séamus Hussey; Jean-Pierre Hugot; Sanja Kolacek; Kaija Leena Kolho; Paolo Lionetti; Anders Paerregaard; Alexander Potapov; Risto Rintala; Daniela E Serban; Annamaria Staiano; Brian Sweeny; Gigi Veerman; Gabor Veres; David C Wilson; Frank M Ruemmele Journal: J Pediatr Gastroenterol Nutr Date: 2012-09 Impact factor: 2.839